Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - STOCKHEAD.COM.AU - A La Une - 02/Sep 01:28
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
Imugene's stock has surged this morning, on promising Phase 1b results for its azer-cel allogeneic CAR T-cell therapy. ...
Articles similaires
CAR-T Cell Therapy And Bone Marrow Transplant Improving Lymphoma Outcomes: Experts
Advanced treatments like CAR-T cell therapy and bone marrow transplants are significantly improving outcomes for lymphoma patients, experts highlight...
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
Experimental mRNA Cancer Vaccine Shows Promise in Phase 1 Trial
An experimental mRNA cancer vaccine shows promising results in a Phase 1 trial, potentially offering new hope for advanced-stage cancer patients.
First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
CAR T-Cell Therapy: FDA Warning on Secondary Cancer Risks
Highlights: Secondary Primary Malignancy rates did not significantly differ among various CAR T-cell therapies or c
CAR T-Cell Therapy: FDA Warning on Secondary Cancer Risks
Highlights: Secondary Primary Malignancy rates did not significantly differ among various CAR T-cell therapies or c
CAR T-Cell Therapy: FDA Warning on Secondary Cancer Risks
Learn why the FDA has mandated boxed warnings for CAR T-cell therapies, highlighting the risks of secondary malignancies.
Les derniers communiqués
-
Aucun élément